S&P 500

5.222,68

0,16%

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

0RU5

Bergenbio Asa (0RU5)

Bergenbio Asa

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0RU5

1 2 3 4 5 6 7 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
22/08/2023	10h50	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
22/08/2023	10h45	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
26/05/2023	15h07	PR Newswire (US)	BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue	LSE:0RU5	Bergenbio Asa
25/04/2023	18h26	PR Newswire (US)	BerGenBio ASA: Proposed partially underwritten rights issue	LSE:0RU5	Bergenbio Asa
18/04/2023	07h23	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
18/04/2023	07h20	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
09/03/2023	11h22	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
09/03/2023	11h20	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
16/02/2023	07h32	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
16/02/2023	07h30	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
15/02/2023	17h35	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
15/02/2023	17h31	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
02/02/2023	07h17	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
02/02/2023	07h15	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
15/11/2022	07h10	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
15/11/2022	07h07	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
25/10/2022	07h37	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
25/10/2022	07h34	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
11/10/2022	07h36	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
11/10/2022	07h34	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
27/09/2022	15h31	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
27/09/2022	15h28	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
23/08/2022	07h36	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
23/08/2022	07h34	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
04/05/2022	07h29	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
04/05/2022	07h27	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
26/04/2022	07h13	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
26/04/2022	07h12	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
11/04/2022	07h12	PR Newswire (US)	BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer	LSE:0RU5	Bergenbio Asa
07/04/2022	14h20	PR Newswire (US)	BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021	LSE:0RU5	Bergenbio Asa